Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.
Frequently asked questions
What sector does Amniotics AB (AMNI) operate in?
Amniotics AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Amniotics AB (AMNI) current stock price?
As of the latest data, Amniotics AB stock price is SEK 0.01, with a previous close of SEK 0.01.
What is Amniotics AB (AMNI) current market capitalization?
Amniotics AB market cap is approximately 13.67 million.
What is Amniotics AB (AMNI) Earnings Per Share (EPS)?
The trailing EPS is SEK 0.65.
What is Amniotics AB (AMNI) Price-to-Earnings (P/E) ratio?
Amniotics AB current P/E ratio is 0.01.
Does Amniotics AB (AMNI) pay dividends?
No. Amniotics AB does not pay a dividend.
What is Amniotics AB (AMNI) beta (volatility) score?
Amniotics AB has a beta of 0.526, indicating lower volatility than the overall market.
